Document is current

Article History

Received: 12 November 2024

Accepted: 1 October 2025

First Online: 6 November 2025

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. The trial was approved by The Regional Committee for Medical Research Ethics Southeast Norway (32637), assessed by the Data Protection Officer (Oslo University Hospital) and registered at ClinicalTrials.gov (NCT04480203). Reporting of this trial follows the CONSORT 2010 checklist. Consent to participate. Informed consent was obtained from all participants. Submitting the initial digital CABC survey implied consent. Participants had to read the informed consent and actively confirm that they “consent to participate by filling out and return this survey”.

: The authors KS, SL, AM, YMG, EB, IML, TÅM, AB, CMR, CEK, IM and GU have no relevant financial or non-financial interests to disclose.LSN is an unpaid board member of dHealth AS, which seeks to commercialize the original StressProffen program, but does not have any financial interest in the company or applicationTC is Co-chief investigator on a National Institute for Health and Care Research (NIHR) program grant in the UK testing a modified acceptance and commitment therapy intervention to improve quality of life for people with a range of cancers in the posttreatment phase. MHA is a consultant for Blue Note Therapeutics and Atlantis Healthcare, both digital health software companies. LEC receives royalties for 2 mindfulness book titles, and from eMindful for an online mindfulness-based cancer recovery program. HRE is a co-founder and a shareholder of a company offering lectures, education, and supervision about stress and coping (Stressprofessorene AS). HRE has no commercial interest in the StressProffen program. All authors have no competing-interest.